KD Logo

Recent Insider Activity Could Benefit Kymera Therapeutics Inc (KYMR)

Kymera Therapeutics Inc’s recently made public that its Chief Operating Officer Chadwick Jeremy G unloaded Company’s shares for reported $90105.0 on May 23 ’24. In the deal valued at $34.99 per share,2,575 shares were sold. As a result of this transaction, Chadwick Jeremy G now holds 44,183 shares worth roughly $1.5 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Booth Bruce sold 71,764 shares, generating $2,903,336 in total proceeds. Upon selling the shares at $40.46, the Director now owns 806,697 shares.

Before that, Booth Bruce sold 55,779 shares. Kymera Therapeutics Inc shares valued at $2,229,927 were divested by the Director at a price of $39.98 per share. As a result of the transaction, Booth Bruce now holds 819,151 shares, worth roughly $27.89 million.

Oppenheimer initiated its Kymera Therapeutics Inc [KYMR] rating to an Outperform in a research note published on April 22, 2024; the price target was $53. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid February with a ‘”a Peer perform”‘ rating. JP Morgan also remained covering KYMR and has increased its forecast on January 04, 2024 with a “an Overweight” recommendation from previously “Neutral” rating. BofA Securities revised its rating on January 03, 2024. It rated KYMR as “a Neutral” which previously was an “a Buy”.

Price Performance Review of KYMR

On Friday, Kymera Therapeutics Inc [NASDAQ:KYMR] saw its stock fall -0.55% to $34.05. Over the last five days, the stock has lost -2.58%. Kymera Therapeutics Inc shares have risen nearly 33.74% since the year began. Nevertheless, the stocks have risen 16.17% over the past one year. While a 52-week high of $45.31 was reached on 02/27/24, a 52-week low of $9.60 was recorded on 01/04/24. SMA at 50 days reached $36.76, while 200 days put it at $27.09. A total of 0.43 million shares were traded, compared to the trading of 0.5 million shares in the previous session.

Levels Of Support And Resistance For KYMR Stock

The 24-hour chart illustrates a support level at 33.33, which if violated will result in even more drops to 32.60. On the upside, there is a resistance level at 35.39. A further resistance level may holdings at 36.72. The Relative Strength Index (RSI) on the 14-day chart is 41.00, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.67, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.42%. Stochastics %K at 14.24% indicates the stock is a buying.

Most Popular